Wednesday 12 March 2014

Sun Pharma up 3%, arm gets USFDA nod for schizophrenia drug

Investors are lapping up shares of  Sun Pharmaceutical Industries on Wednesday as its subsidiary Caraco has received approval from US Food and Drug Administration (FDA) for Risperidone oral tablets. The stock rallied as much as 3.4 percent intraday. 

At 10:29 hours IST, the stock rose 3.14 percent to Rs 598.60 on the Bombay Stock Exchange. It rallied more than 40 percent in last one year. 

Risperidone oral tablet is used for the treatment of schizophrenia (a mental disorder). Meanwhile, the healthcare major on Monday had voluntarily recalled 2,528 bottles of its generic version of diabetes drug Glumetza from US-based Santarus Inc after it received a customer complaint.

No comments:

Post a Comment